https://www.kdtvc.com/ https://www.kdtvc.com/our-team https://www.kdtvc.com/portfolio https://www.kdtvc.com/news-and-press https://www.kdtvc.com/contact https://www.kdtvc.com/404 https://www.kdtvc.com/news-and-press/kdt-ventures-nabs-over-100-million-for-early-stage-investments https://www.kdtvc.com/news-and-press/ngm-bio-and-kdt-ventures-enter-into-worldwide-license https://www.kdtvc.com/news-and-press/zymochem-closes-21m-series-a-round-led-by-breakout-ventures-with-investments-from-lululemon-and-toyota-ventures https://www.kdtvc.com/news-and-press/terray-therapeutics-announces-multi-target-collaboration-with-bristol-myers-squibb https://www.kdtvc.com/news-and-press/terray-therapeutics-announces-investment-from-nvidia-to-enable-generative-ai-design-for-drug-discovery https://www.kdtvc.com/news-and-press/zymochem-awarded-4-million-to-manufacture-bio-based-polymers https://www.kdtvc.com/news-and-press/bayer-partnered-azitra-hopes-to-apply-7.5m-ipo-proceeds-to-near-clinical-dermatology-pipeline https://www.kdtvc.com/news-and-press/months-after-adding-60m-to-coffers-ai-startup-terray-nabs-discovery-pact-with-google%E2%80%99s-calico https://www.kdtvc.com/news-and-press/%E2%80%98pluck-those-diamonds%E2%80%99-bayer%E2%80%99s-vividion-eyes-up-to-nine-oncology-targets-from-duke-spinout https://www.kdtvc.com/news-and-press/ginkgo-bioworks-acquires-circular-rna-biotech-circularis https://www.kdtvc.com/news-and-press/https-www.newswire.com-news-kdt-ventures-celebrates-5-year-anniversary-close-of-oversubscribed-21833458 https://www.kdtvc.com/news-and-press/sid-mukherjee-lew-cantley-behind-new-cancer-biotech-with-food-drug-combo-treatment-ambitions https://www.kdtvc.com/news-and-press/the-world%E2%80%99s-most-innovative-companies-of-2022 https://www.kdtvc.com/news-and-press/start-up-raises-60-million-for-platform-that-does-drug-discovery-on-microarrays